about
A review of the medical treatment of primary sclerosing cholangitis in the 21st centuryBiochemical characterization of human GMP synthetaseThe glutamine hydrolysis function of human GMP synthetase. Identification of an essential active site cysteineProspective, systematically recorded mycophenolate safety data in Graves' orbitopathy.Proteomic analysis of the effects of the immunomodulatory mycotoxin deoxynivalenol.High incidence of severe acute graft-versus-host disease with tacrolimus and mycophenolate mofetil in a large cohort of related and unrelated allogeneic transplantation patients.Review of the immunosuppressant enteric-coated mycophenolate sodium.Evaluation of potential interactions between mycophenolic acid derivatives and proton pump inhibitors.Advances in pharmacotherapy to treat kidney transplant rejection.Validation of the cell line LS180 as a model for study of the gastrointestinal toxicity of mycophenolic acid.In-vitro influence of mycophenolate mofetil (MMF) and Ciclosporin A (CsA) on cytokine induced killer (CIK) cell immunotherapy.Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies?Micophenolat Mofetil versus Azathioprine: effects on renal graft function in early posttransplant period.De novo GMP synthesis is required for axon guidance in Drosophila.Effect of mycophenolate mofetil on the progression of adriamycin nephropathy.Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation.Suppression of proliferation and phosphorylation of Jak3 and STAT5 in malignant T-cell lymphoma cells by derivatives of octylamino-undecyl-dimethylxanthine.
P2860
Q26771816-8F105F25-F6D3-4946-8D3A-F0566D89D157Q28118532-DD4F7DF3-A20A-4047-8362-B74FD7C1B0D3Q28289430-8CACFF15-2DFE-4399-AFFD-2A981A9D4D2CQ31047067-EDA0EF7F-B41D-4B7A-A99C-61F92722B5A7Q33861765-94625127-71D0-49D6-9163-E4BD73095772Q33950015-8CBE13BD-D441-4978-9923-1B11704CDD7DQ35784063-9FB3C9A4-FFD7-4B0A-8191-9BE075C63753Q38027466-4672DEBB-FD28-484E-9F39-86A3FDD235FBQ38544529-A04E9463-9208-4714-B6AC-AD19EC5A0BADQ38704055-7EF694BE-F595-42B0-906A-1074FB83842AQ39399171-B072BE7F-DC6E-40C8-8C66-D9BEAC1BBC3EQ40672537-90A0DA06-73D4-477A-92E4-5B0D6DEB8074Q42375665-E8B68286-A8F9-4B84-97E0-30BA6855EA33Q42712825-A347026B-416B-4ACE-8460-19034F96CE4CQ43810613-9DEF4C5E-5D93-469F-BC97-053D66C946E9Q46972643-96DAFDC0-1850-4F25-962B-2FE305B93A60Q48011074-E1DC5E6F-E2EF-4832-BEC5-89F0EF86BCD6
P2860
description
1993 nî lūn-bûn
@nan
1993 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Immunosuppressive activity of mycophenolate mofetil.
@ast
Immunosuppressive activity of mycophenolate mofetil.
@en
Immunosuppressive activity of mycophenolate mofetil.
@nl
type
label
Immunosuppressive activity of mycophenolate mofetil.
@ast
Immunosuppressive activity of mycophenolate mofetil.
@en
Immunosuppressive activity of mycophenolate mofetil.
@nl
prefLabel
Immunosuppressive activity of mycophenolate mofetil.
@ast
Immunosuppressive activity of mycophenolate mofetil.
@en
Immunosuppressive activity of mycophenolate mofetil.
@nl
P2860
P1476
Immunosuppressive activity of mycophenolate mofetil.
@en
P2093
A C Allison
P2860
P304
P356
10.1111/J.1749-6632.1993.TB35881.X
P407
P577
1993-06-01T00:00:00Z